Profile data is unavailable for this security.
About the company
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The Company uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.
- Revenue in USD (TTM)0.00
- Net income in USD-34.63m
- Incorporated2020
- Employees14.00
- LocationeFFECTOR Therapeutics Inc142 North Cedros AvenueSuite B, Suite ASOLANA BEACH 92075United StatesUSA
- Phone+1 (858) 925-8215
- Fax+1 (302) 655-5049
- Websitehttps://effector.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| eFFECTOR Therapeutics Inc | 0.00 | -34.63m | 203.47k | 14.00 | -- | 0.2041 | -- | -- | -13.31 | -13.31 | 0.00 | 0.2119 | 0.00 | -- | -- | 0.00 | -141.18 | -- | -- | -- | -- | -- | -- | -- | -- | -17.12 | 0.9581 | -- | -100.00 | -- | -58.00 | -- | -- | -- |
| Health Advance Inc | -100.00bn | -100.00bn | 204.37k | 3.00 | -- | 0.0473 | -- | -- | -- | -- | -- | 0.0212 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0356 | -- | 100.00 | -- | -21.75 | -- | -- | -- |
| CNBX Pharmaceuticals Inc | 230.08k | -1.21m | 220.89k | 2.00 | -- | -- | -- | 0.9601 | -0.0458 | -0.0458 | 0.0081 | -0.0789 | 0.6201 | -- | -- | 115,040.00 | -325.63 | -73.32 | -- | -99.80 | 14.96 | -- | -525.10 | -3,970.88 | -- | -1.34 | -- | -- | -- | 111.90 | 0.3497 | -- | -- | -- |
| Propanc Biopharma Inc | 0.00 | -2.46m | 223.10k | 1.00 | -- | -- | -- | -- | -0.3033 | -0.3033 | 0.00 | -0.0337 | 0.00 | -- | -- | -- | -2,440.90 | -4,945.87 | -- | -- | -- | -- | -- | -- | -- | -1.70 | -- | -- | -- | -- | -17.63 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Sabby Management LLCas of 30 Jun 2024 | 352.08k | 7.48% |
| Parallel Advisors LLCas of 30 Jun 2024 | 67.74k | 1.44% |
| UBS Securities LLCas of 30 Jun 2024 | 61.67k | 1.31% |
| HRT Financial LLCas of 30 Jun 2024 | 21.53k | 0.46% |
| Jane Street Capital LLCas of 30 Jun 2024 | 18.67k | 0.40% |
| Virtu Americas LLCas of 30 Jun 2024 | 18.02k | 0.38% |
| Sea Otter Advisors LLCas of 30 Jun 2024 | 10.56k | 0.22% |
| Tower Research Capital LLCas of 30 Jun 2024 | 9.81k | 0.21% |
| RBC Dominion Securities, Inc.as of 30 Jun 2024 | 546.00 | 0.01% |
| Barclays Capital, Inc.as of 30 Jun 2024 | 100.00 | 0.00% |
